文献速递细菌感染、耐药与抗菌药物

MYCOPLASMA IST3 泌尿生殖道支原体检测国际多中心评估

Evaluation of the MYCOPLASMA IST3 urogenital mycoplasma assay in an international multicentre trial.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

研究在法国、塞尔维亚和英国多中心评估 MYCOPLASMA IST3 对泌尿生殖道支原体的检测性能,共 516 份临床样本。结果显示对 Ureaplasma 属和 M. hominis 的菌种鉴定灵敏度和特异度均较高,耐药筛查主要错误率低,菌量估计在允许 ±10 倍变异时准确性提升。

要点

  • 对 Ureaplasma 属鉴定灵敏度 98.4%、特异度 99.7%。
  • 对 M. hominis 鉴定灵敏度 95.7%、特异度 100%。
  • 耐药筛查主要错误率 Ureaplasma 1.8%、M. hominis 1.5%。

核心结论

  • MYCOPLASMA IST3 经重新设计后能独立、准确地筛查 M. hominis 和 Ureaplasma 属的耐药性,包括混合感染,且阈值符合 CLSI 标准。
  • 其特异性、灵敏度和菌量估计与确认方法高度相关。

研究设计与样本

  • 国际多中心评估研究,在法国、塞尔维亚和英国采集 516 份临床样本。
  • 样本类型包括外阴阴道/宫颈或尿道拭子(干拭子或 eSwab®)、精液和尿液,并加入 80 株特征明确的对照菌株进行盲法分析。
  • 以培养和分子金标准方法为参照,评估检测、鉴定、菌量计数和耐药性判断的准确性。

主要发现

  • 相对琼脂菌落形态联合定量 PCR 标准,Ureaplasma 属鉴定灵敏度 98.4%、特异度 99.7%。
  • M. hominis 鉴定灵敏度 95.7%、特异度 100%。
  • 非稀释法菌量估计准确率:M. hominis 83.7%,Ureaplasma 属 86.3%;允许 ±10 倍变异时分别升至 94.2% 和 100%。
  • 耐药准确性:Ureaplasma 属 605 项单项检测中 11 项与金标准不符,主要错误率 1.8%;M. hominis 917 项中 14 项不符,主要错误率 1.5%。

关键数值与推荐

  • Ureaplasma 属鉴定:灵敏度 98.4%,特异度 99.7%。
  • M. hominis 鉴定:灵敏度 95.7%,特异度 100%。
  • 菌量估计准确率:M. hominis 83.7%,Ureaplasma 属 86.3%;±10 倍变异允许下分别为 94.2% 和 100%。
  • 耐药主要错误率:Ureaplasma 属 1.8%(11/605),M. hominis 1.5%(14/917)。

临床怎么用

  • MYCOPLASMA IST3 可用于泌尿生殖道支原体的检测、鉴定和耐药筛查,尤其适合需要独立耐药信息的场景。
  • 对混合感染仍能提供准确的耐药筛查结果,阈值符合 CLSI 标准。
  • 菌量估计在允许 ±10 倍变异时准确性更高,临床解读时应考虑该方法学差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the accuracy, susceptibility and specificity of MYCOPLASMA IST3, the next generation of the most popular culture-based in vitro diagnostic device designed to detect, identify and test the susceptibility of urogenital mycoplasma infections. METHODS: MYCOPLASMA IST3 was evaluated against culture- and molecular-based gold standard methodologies to detect, identify, enumerate and determine antimicrobial resistance for Mycoplasma hominis and Ureaplasma species in 516 clinical samples collected across France, Serbia and the UK. Sample types included vulvovaginal/endocervical or urethral swabs (dry swab or eSwab®), semen and urine samples, which included blinded analysis following addition of a panel of 80 characterized control strains. RESULTS: Overall species identification was excellent for both Ureaplasma spp. (98.4% sensitivity, 99.7% specificity) and M. hominis (95.7% sensitivity, 100% specificity) relative to combined colony morphology on agar and quantitative PCR standards. Non-dilution-based bacterial load estimation by the assay was accurate between 83.7% (M. hominis) and 86.3% (Ureaplasma spp.) of the time (increased to 94.2% and 100%, respectively, if ±10-fold variance was allowed) relative to colonies counted on agar. Resistance accuracy for Ureaplasma spp. varied from gold standards for only 11/605 of individual tests (major error rate = 1.8%) and for 14/917 individual tests for M. hominis (major error rate = 1.5%). CONCLUSIONS: The redesigned MYCOPLASMA IST3 assay eliminated previous shortcomings by providing independent accurate resistance screening of M. hominis and Ureaplasma species, even in mixed infections, with CLSI-compliant thresholds. Specificity, sensitivity and enumeration estimates correlated closely with the confirmatory methods.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Boostrom I, Bala Y, Vasic JM, et al. Evaluation of the MYCOPLASMA IST3 urogenital mycoplasma assay in an international multicentre trial. J Antimicrob Chemother. 2021. PMID: 34477840. doi:10.1093/jac/dkab320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。